 So we're hoping that rapamycin can target the underlying cause, which is aging, to improve patients that have periodontal disease. Participants will take varying doses of rapamycin for eight weeks. Ahn will also measure changes in participants' microbiomes and their biological clocks. Allison Aubrey, NPR News.